BMO Capital Upgrades Amylin Pharmaceuticals (AMLN) to Outperform, Raises Price Target to $17
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
BMO Capital upgraded shares of Amylin Pharmaceuticals (NASDAQ: AMLN) to an Outperform rating from its previous rating of Market Perform. The firm also raised its price target from $12 to $17.00.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $9.73 yesterday.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $9.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Johnson Rice Upgrades Magnolia Oil & Gas Corp. (MGY) to Accumulate
- JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
Create E-mail Alert Related Categories
UpgradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
